Baseline patient characteristics
| Characteristic . | All patients, n = 340 . |
|---|---|
| Age, median (range), y | 23.5 (1-78) |
| Sex, n (%) | |
| Male | 197 (57.9) |
| Female | 143 (42.1) |
| Primary diagnosis, n (%) | |
| Hematologic malignancy | 188 (55.3) |
| Solid malignancy | 150 (44.1) |
| Nonmalignant conditions | 2 (0.6) |
| Hematologic malignancies, n (%) | |
| ALL | 46 (24.5) |
| AML | 11 (5.9) |
| CLL | 11 (5.9) |
| CML | 8 (4.3) |
| NHL | 41 (21.8) |
| HL | 54 (28.7) |
| MM | 7 (3.7) |
| Others | 10 (5.3) |
| Solid tumors, n (%) | |
| Neuroblastoma | 33 (22.0) |
| Glioblastoma | 19 (12.7) |
| Lung cancer | 10 (6.7) |
| Osteosarcoma | 52 (34.7) |
| Head and neck | 16 (10.7) |
| Liver tumors | 8 (5.3) |
| Others | 12 (8.0) |
| Transplant, n (%) | |
| Autologous | 99 (29.1) |
| Allogeneic | 83 (24.4) |
| No transplant | 158 (46.5) |
| History of radiation therapy, n = 339 (%) | |
| No | 137 (40.4) |
| Yes | 202 (59.6) |
| Median follow-up (range), mo | 14.9 (<1-183) |
| Cumulative follow-up, y | 1027 |
| Characteristic . | All patients, n = 340 . |
|---|---|
| Age, median (range), y | 23.5 (1-78) |
| Sex, n (%) | |
| Male | 197 (57.9) |
| Female | 143 (42.1) |
| Primary diagnosis, n (%) | |
| Hematologic malignancy | 188 (55.3) |
| Solid malignancy | 150 (44.1) |
| Nonmalignant conditions | 2 (0.6) |
| Hematologic malignancies, n (%) | |
| ALL | 46 (24.5) |
| AML | 11 (5.9) |
| CLL | 11 (5.9) |
| CML | 8 (4.3) |
| NHL | 41 (21.8) |
| HL | 54 (28.7) |
| MM | 7 (3.7) |
| Others | 10 (5.3) |
| Solid tumors, n (%) | |
| Neuroblastoma | 33 (22.0) |
| Glioblastoma | 19 (12.7) |
| Lung cancer | 10 (6.7) |
| Osteosarcoma | 52 (34.7) |
| Head and neck | 16 (10.7) |
| Liver tumors | 8 (5.3) |
| Others | 12 (8.0) |
| Transplant, n (%) | |
| Autologous | 99 (29.1) |
| Allogeneic | 83 (24.4) |
| No transplant | 158 (46.5) |
| History of radiation therapy, n = 339 (%) | |
| No | 137 (40.4) |
| Yes | 202 (59.6) |
| Median follow-up (range), mo | 14.9 (<1-183) |
| Cumulative follow-up, y | 1027 |
ALL, acute lymphocytic leukemia; AML, acute myelocytic leukemia; CML, chronic myelocytic leukemia; MM, multiple myeloma; TBI, total body irradiation.